412 related articles for article (PubMed ID: 19009291)
1. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.
Galustian C; Meyer B; Labarthe MC; Dredge K; Klaschka D; Henry J; Todryk S; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB; Dalgleish AG
Cancer Immunol Immunother; 2009 Jul; 58(7):1033-45. PubMed ID: 19009291
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological properties of thalidomide and its analogues.
De Sanctis JB; Mijares M; Suárez A; Compagnone R; Garmendia J; Moreno D; Salazar-Bookaman M
Recent Pat Inflamm Allergy Drug Discov; 2010 Jun; 4(2):144-8. PubMed ID: 20307255
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of Foxp3(+) gammadelta T cells in mouse and human.
Kang N; Tang L; Li X; Wu D; Li W; Chen X; Cui L; Ba D; He W
Immunol Lett; 2009 Aug; 125(2):105-13. PubMed ID: 19539651
[TBL] [Abstract][Full Text] [Related]
4. Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide.
Henry JY; Labarthe MC; Meyer B; Dasgupta P; Dalgleish AG; Galustian C
Immunology; 2013 Jul; 139(3):377-85. PubMed ID: 23374145
[TBL] [Abstract][Full Text] [Related]
5. Role of Thalidomide on the Expression of OX40, 4-1BB, and GITR in T Cell Subsets.
Kim BS; Kim JY; Kim EJ; Lee JG; Joo DJ; Huh KH; Kim MS; Kim YS
Transplant Proc; 2016 May; 48(4):1270-4. PubMed ID: 27320601
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory properties of thalidomide analogs: pomalidomide and lenalidomide, experimental and therapeutic applications.
Bodera P; Stankiewicz W
Recent Pat Endocr Metab Immune Drug Discov; 2011 Sep; 5(3):192-6. PubMed ID: 21913886
[TBL] [Abstract][Full Text] [Related]
7. Properties of thalidomide and its analogues: implications for anticancer therapy.
Teo SK
AAPS J; 2005 Mar; 7(1):E14-9. PubMed ID: 16146335
[TBL] [Abstract][Full Text] [Related]
8. Human anti-inflammatory macrophages induce Foxp3+ GITR+ CD25+ regulatory T cells, which suppress via membrane-bound TGFbeta-1.
Savage ND; de Boer T; Walburg KV; Joosten SA; van Meijgaarden K; Geluk A; Ottenhoff TH
J Immunol; 2008 Aug; 181(3):2220-6. PubMed ID: 18641362
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic induced human FOXP3(+)IFN-gamma(+) T cells exhibit selective suppressive capacity.
Stroopinsky D; Avivi I; Rowe JM; Avigan D; Katz T
Eur J Immunol; 2009 Oct; 39(10):2703-15. PubMed ID: 19634189
[TBL] [Abstract][Full Text] [Related]
10. Regulatory T cells in human autoimmune thyroid disease.
Marazuela M; García-López MA; Figueroa-Vega N; de la Fuente H; Alvarado-Sánchez B; Monsiváis-Urenda A; Sánchez-Madrid F; González-Amaro R
J Clin Endocrinol Metab; 2006 Sep; 91(9):3639-46. PubMed ID: 16804051
[TBL] [Abstract][Full Text] [Related]
11. Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF.
Ablamunits V; Bisikirska B; Herold KC
Eur J Immunol; 2010 Oct; 40(10):2891-901. PubMed ID: 21038470
[TBL] [Abstract][Full Text] [Related]
12. Novel Foxp3(-) IL-10(-) Regulatory T-cells Induced by B-Cells Alleviate Intestinal Inflammation in Vivo.
Shao TY; Hsu LH; Chien CH; Chiang BL
Sci Rep; 2016 Sep; 6():32415. PubMed ID: 27581189
[TBL] [Abstract][Full Text] [Related]
13. Methionine enkephalin (MENK) inhibits tumor growth through regulating CD4+Foxp3+ regulatory T cells (Tregs) in mice.
Li X; Meng Y; Plotnikoff NP; Youkilis G; Griffin N; Wang E; Lu C; Shan F
Cancer Biol Ther; 2015; 16(3):450-9. PubMed ID: 25701137
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma.
Pierceall WE; Amatangelo MD; Bahlis NJ; Siegel DS; Rahman A; Van Oekelen O; Neri P; Young M; Chung W; Serbina N; Parekh S; Agarwal A; Thakurta A
Clin Cancer Res; 2020 Nov; 26(22):5895-5902. PubMed ID: 32928795
[TBL] [Abstract][Full Text] [Related]
15. Enhanced immune-modulatory effects of thalidomide and dexamethasone co-treatment on T cell subsets.
Kim EJ; Lee JG; Kim JY; Song SH; Joo DJ; Huh KH; Kim MS; Kim BS; Kim YS
Immunology; 2017 Dec; 152(4):628-637. PubMed ID: 28758197
[TBL] [Abstract][Full Text] [Related]
16. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models.
Cho SF; Lin L; Xing L; Li Y; Wen K; Yu T; Hsieh PA; Munshi N; Wahl J; Matthes K; Friedrich M; Arvedson T; Anderson KC; Tai YT
Blood Adv; 2020 Sep; 4(17):4195-4207. PubMed ID: 32898244
[TBL] [Abstract][Full Text] [Related]
17. Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model.
Vo MC; Yang S; Jung SH; Chu TH; Lee HJ; Lakshmi TJ; Park HS; Kim HJ; Lee JJ
Front Immunol; 2018; 9():1798. PubMed ID: 30123221
[TBL] [Abstract][Full Text] [Related]
18. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.
Cohen AD; Schaer DA; Liu C; Li Y; Hirschhorn-Cymmerman D; Kim SC; Diab A; Rizzuto G; Duan F; Perales MA; Merghoub T; Houghton AN; Wolchok JD
PLoS One; 2010 May; 5(5):e10436. PubMed ID: 20454651
[TBL] [Abstract][Full Text] [Related]
19. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.
Lopez-Girona A; Mendy D; Ito T; Miller K; Gandhi AK; Kang J; Karasawa S; Carmel G; Jackson P; Abbasian M; Mahmoudi A; Cathers B; Rychak E; Gaidarova S; Chen R; Schafer PH; Handa H; Daniel TO; Evans JF; Chopra R
Leukemia; 2012 Nov; 26(11):2326-35. PubMed ID: 22552008
[TBL] [Abstract][Full Text] [Related]
20. In vivo expansion of CD4+Foxp3+ regulatory T cells mediated by GITR molecules.
Nishioka T; Nishida E; Iida R; Morita A; Shimizu J
Immunol Lett; 2008 Dec; 121(2):97-104. PubMed ID: 18930767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
